{"id":"NCT00529451","sponsor":"Novartis","briefTitle":"Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg","officialTitle":"An Eight Week, Double-blind, Randomized, Multicenter, Parallel Group, Active-controlled Study Comparing the Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg to Ramipril 5 mg in Patients With Essential Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-09","primaryCompletion":"2008-07","completion":"2008-07","firstPosted":"2007-09-14","resultsPosted":"2011-03-25","lastUpdate":"2011-03-25"},"enrollment":1613,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension"],"interventions":[{"type":"DRUG","name":"Aliskiren","otherNames":[]},{"type":"DRUG","name":"Ramipril","otherNames":[]}],"arms":[{"label":"Aliskiren 300 mg","type":"EXPERIMENTAL"},{"label":"Aliskiren 150 mg","type":"EXPERIMENTAL"},{"label":"Aliskiren 75 mg","type":"EXPERIMENTAL"},{"label":"Ramipril 5 mg","type":"ACTIVE_COMPARATOR"}],"summary":"This study is designed to investigate the efficacy, safety and tolerability of aliskiren 300 mg, 150 mg and 75 mg when compared to ramipril 5 mg in patients with essential hypertension.","primaryOutcome":{"measure":"Non-inferiority of Aliskiren 300 mg to Ramipril 5 mg in Change in Mean Sitting Diastolic Blood Pressure (msDBP)","timeFrame":"Baseline and Week 8","effectByArm":[{"arm":"Aliskiren 300 mg","deltaMin":-11.63,"sd":0.44},{"arm":"Ramipril 5 mg","deltaMin":-9.19,"sd":0.44}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":3,"countries":["China","India","Thailand"]},"refs":{"pmids":["33089502"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":331},"commonTop":["Cough"]}}